Sun Pharma Unit Signs Licensing Pact with Pharmazz Inc To Launch Drug To Treat Stroke

Sun Pharmaceutical Industries announced a collaboration with US-based Pharmazz Inc to commercialize a medication used to treat cerebral ischemic stroke in India. One of the business's wholly-owned subsidiaries has entered into a license deal with the biopharmaceutical company based in the United States to commercialize Tyvalzi, a first-in-class novel medicine, in the country. According to the terms of the agreement, Sun Pharma will offer Sovateltide in India under the brand name Tyvalzi (Sovateltide). It was also said that Pharmazz will be entitled to upfront and milestone payments, as well as royalties.

"The Phase 3 clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke," Sun Pharma India Business CEO Kirti Ganorkar said. Tyvalzi is a first-in-class breakthrough medicine that can help stroke patients enhance their quality of life, he noted. For the treatment of ischemic stroke, the medication can be taken within 24 hours. The present therapy alternatives have a limited time window of 4-5 hours, restricting their use in the majority of patients. "For patients with cerebral ischemic stroke, I believe Sun Pharma is the best partner for Pharmazz to market Tyvalzi," Chairman of the Board of Directors of Pharmazz Anil Gulati stated. On the BSE, Sun Pharma shares were trading 0.47 percent lower at Rs 1,142.60 per share.